Celecoxib: still around, unfortunately.
In France, the Transparency Committee has now given celecoxib their lowest rating for "medical benefits", i.e. no medical advantage. So when will the regulatory agencies finally decide to withdraw it from the market?
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004335:Drug and Narcotic Control; D005602:France; D019981:Health Care Sector; D006801:Humans; D010003:Osteoarthritis / Q000188:drug therapy*; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use
D011720:Pyrazoles; D013449:Sulfonamides